The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The closing price of Ocular Therapeutix Inc (NASDAQ: OCUL) was $7.25 for the day, down -1.76% from the previous closing price of $7.38. In other words, the price has decreased by -$1.76 from its previous closing price. On the day, 0.55 million shares were traded.
Ratios:
Our analysis of OCUL’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 12.94 and its Current Ratio is at 13.01. In the meantime, Its Debt-to-Equity ratio is 0.21 whereas as Long-Term Debt/Eq ratio is at 0.21.
On June 20, 2024, TD Cowen Upgraded its rating to Buy which previously was Hold and also upped its target price recommendation from $7 to $11.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 04 ’25 when Notman Donald sold 11,119 shares for $7.81 per share. The transaction valued at 86,839 led to the insider holds 193,444 shares of the business.
Notman Donald sold 6,301 shares of OCUL for $49,400 on Jan 31 ’25. The insider now owns 204,563 shares after completing the transaction at $7.84 per share. On Feb 04 ’25, another insider, DONALD D NOTMAN JR., who serves as the Officer of the company, bought 11,119 shares for $7.81 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 18.55 while its Price-to-Book (P/B) ratio in mrq is 3.23.
Stock Price History:
Over the past 52 weeks, OCUL has reached a high of $11.77, while it has fallen to a 52-week low of $4.06. The 50-Day Moving Average of the stock is -11.83%, while the 200-Day Moving Average is calculated to be -11.64%.
Shares Statistics:
A total of 156.65M shares are outstanding, with a floating share count of 132.32M. Insiders hold about 15.83% of the company’s shares, while institutions hold 73.34% stake in the company.
